Myriad Genetics (NASDAQ:MYGN) Announces Earnings Results, Beats Expectations By $0.03 EPS
Myriad Genetics (NASDAQ:MYGN) Announces Earnings Results, Beats Expectations By $0.03 EPS
Myriad Genetics (NASDAQ:MYGN – Get Rating) released its quarterly earnings results on Thursday. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.03, Briefing.com reports. The company had revenue of $179.30 million for the quarter, compared to the consensus estimate of $170.05 million. Myriad Genetics had a negative net margin of 2.62% and a negative return on equity of 3.44%. Myriad Genetics's revenue was down 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.03 earnings per share. Myriad Genetics updated its FY22 guidance to $(0.10)-$0.00 EPS and its FY 2022 guidance to -$0.10-0 EPS.
周四,纳斯达克(MYGN-GET Rating)发布了季度收益报告。据Briefing.com报道,该公司公布本季度每股收益(EPS)为0.04美元,比分析师普遍预期的0.01美元高出0.03美元。该公司本季度营收为1.793亿美元,而市场普遍预期为1.705亿美元。Myriad Genetics的净利润率为负2.62%,股本回报率为负3.44%。Myriad Genetics的收入同比下降了5.3%。去年同期,该公司每股收益为0.03美元。Myriad Genetics将其22财年每股收益指引更新为0.10-0.00美元,将2022财年每股收益指引更新为-0.10-0美元。
Myriad Genetics Price Performance
数不胜数的基因产品性价比
Shares of MYGN opened at $27.46 on Friday. The company's fifty day simple moving average is $20.69 and its 200-day simple moving average is $22.87. Myriad Genetics has a twelve month low of $16.02 and a twelve month high of $36.95.
上周五,MYGN的股价开盘报27.46美元。该公司的50日简单移动均线切入位为20.69美元,200日简单移动均线切入位为22.87美元。Myriad Genetics的12个月低点为16.02美元,12个月高位为36.95美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
A number of equities research analysts recently issued reports on MYGN shares. Cowen set a $25.00 price target on shares of Myriad Genetics in a research note on Tuesday, July 19th. The Goldman Sachs Group decreased their price target on shares of Myriad Genetics from $26.00 to $23.00 and set a "sell" rating on the stock in a research note on Tuesday, April 19th. StockNews.com downgraded shares of Myriad Genetics from a "buy" rating to a "hold" rating in a research note on Wednesday, July 13th. SVB Leerink increased their target price on shares of Myriad Genetics from $26.00 to $30.00 and gave the company a "market perform" rating in a research note on Friday. Finally, TheStreet downgraded shares of Myriad Genetics from a "c-" rating to a "d+" rating in a research note on Friday, June 3rd.
一些股票研究分析师最近发布了关于MYGN股票的报告。考恩在7月19日星期二的一份研究报告中为Myriad Genetics的股票设定了25.00美元的目标价。4月19日,周二,高盛夫妇在一份研究报告中将Myriad Genetics的股票目标价从26.00美元下调至23.00美元,并对该股设定了“卖出”评级。在7月13日星期三的一份研究报告中,StockNews.com将Myriad Genetics的股票评级从“买入”下调至“持有”。SVB Leerink在周五的一份研究报告中将Myriad Genetics的目标价从26.00美元上调至30.00美元,并给予该公司“市场表现”的评级。最后,华尔街在6月3日星期五的一份研究报告中将Myriad Genetics的股票评级从“c-”下调至“d+”。
Insider Transactions at Myriad Genetics
Myriad Genetics的内幕交易
Institutional Inflows and Outflows
机构资金流入和流出
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can grew its holdings in Myriad Genetics by 147.9% during the 1st quarter. Bank of Montreal Can now owns 65,458 shares of the company's stock worth $1,687,000 after acquiring an additional 39,052 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Myriad Genetics by 55.6% in the 1st quarter. MetLife Investment Management LLC now owns 42,669 shares of the company's stock valued at $1,075,000 after buying an additional 15,255 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Myriad Genetics in the 1st quarter valued at about $648,000. American Century Companies Inc. boosted its holdings in shares of Myriad Genetics by 22.3% in the 1st quarter. American Century Companies Inc. now owns 16,607 shares of the company's stock valued at $418,000 after buying an additional 3,027 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Myriad Genetics in the 1st quarter valued at about $399,000. 97.44% of the stock is currently owned by institutional investors.
对冲基金和其他机构投资者最近增持或减持了该业务的股份。蒙特利尔银行在第一季度对Myriad Genetics的持股增加了147.9%。蒙特利尔银行在上个季度增持了39,052股后,现在可以持有65,458股该公司股票,价值1,68.7万美元。大都会人寿投资管理有限责任公司在第一季度增持了Myriad Genetics的股票55.6%。大都会人寿投资管理有限责任公司目前持有42,669股该公司股票,价值1,075,000美元,上一季度又购买了15,255股。汇丰控股在第一季度购买了Myriad Genetics的新股,价值约64.8万美元。美国世纪公司第一季度增持Myriad Genetics股票22.3%。美国世纪公司目前持有16,607股该公司股票,价值41.8万美元,上一季度又购买了3,027股。最后,Walleye Capital LLC在第一季度购买了Myriad Genetics的新股,价值约39.9万美元。97.44%的股票目前由机构投资者持有。
Myriad Genetics Company Profile
万得基因公司简介
(Get Rating)
(获取评级)
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Myriad Genetics,Inc.是一家基因测试和精密药物公司,在美国和国际上开发基因测试并将其商业化。该公司提供分子诊断测试,用于肿瘤学、妇女和心理健康应用。它提供了MyRisk遗传性癌症测试,这是一种评估遗传性癌症风险的DNA测序测试;BRAC分析CDX种系伴随诊断测试,这是一种DNA测序测试,有助于确定转移性乳腺癌、卵巢癌、转移性胰腺癌或转移性前列腺癌患者的治疗方案,这些患者具有有害或疑似有害的种系BRCA变异;以及MyChoice CDX伴生诊断测试,这是一种肿瘤测试,可以确定卵巢癌患者的同源重组缺陷状态。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Myriad Genetics (MYGN)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免费获取StockNews.com关于Myriad遗传学的研究报告(MYGN)
- MarketBeat:回顾中的一周8/1-8/5
- 如何利用高贝塔系数股票最大化你的投资利润
- 克罗诺斯集团(Cronos Group Inc.)营收上升,是时候收购了吗?
- Beyond Meat不是没有希望,而且它很便宜
- 苹果为何可能在年底创下历史新高
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Myriad Genetics Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收Myriad Genetics和相关公司的最新新闻和分析师评级的每日摘要。